cyrilzakka/clinical-trials huggingface dataset:
Prothrombotic Biomarkers and Ovarian Stimulation

The aim of this study is to assess the impact of different protocols used for ovarian stimulation during in vitro fertilization procedures (IVF) on prothrombotic biomarkers (blood coagulation markers associated with thromboembolic events) in the units of reproductive medicine in two university hospitals (HUG, Geneva and CHUV, Lausanne).

HEMO-STIM is a prospective multicentric cohort study of subfertile women undergoing ART. It is an epidemiologic observational study. All women older than 18 years attending the reproductive medicine unit (UMREG, Geneva, HUG or UMR, Lausanne, CHUV) and undergoing an IVF have been and will be recruited consecutively and included. The type of stimulation protocol used is recorded.

All measurements (specific haemostasis test with a thrombin generation assay before and after adjunction of APC) that are part of the study will be performed in the HUG laboratories in order to limit inter-dosage variability.

The 1st blood test will be performed at inclusion in the absence of any hormonal treatment (T1). A 2nd blood test will be performed on the day of ovulation triggering (T2). A 3rd blood test will be performed 7 days after ovulation triggering (T3).

The comparison of different protocols has never been performed and data on the effect of antagonist protocols for IVF on haemostasis are lacking. The measurement of intermediate biomarkers of thromboembolic risk during different IVF stimulation protocols (agonists and antagonists) would allow the comparison of their thrombotic profile and to optimize the risk/benefit ratio during ART by prescribing protocols at lower vascular risk, in particular in women identified as being at risk for thromboembolic events.

Eligibility Criteria:
Inclusion Criteria:

* Women older than 18 years
* Sub-fertile and undergoing IVF

Exclusion Criteria:

* \>43 years old
Inhaled Milrinone in Cardiac Surgery

The purpose of this study is to investigate the concentration-effect relationship of inhaled milrinone after prophylactic administration in cardiac surgical patients with preoperative pulmonary hypertension undergoing cardiopulmonary bypass.

Milrinone elimination will be verify with blood and urine samples analysis.

Eligibility Criteria:
Inclusion Criteria:

* Patients scheduled for elective cardiac surgery under CPB
* High risk patients: NYHA class II-III
* Preoperative diagnostic of pulmonary hypertension:

  * Systolic pulmonary artery pressure (sPAP) \> 35 mm Hg; or
  * Mean pulmonary artery pressure (mPAP) \> 25 mm Hg; or
  * mAP/mPAP \< 3.0 (after induction of anesthesia).

Exclusion Criteria:

* Open Heart Surgery
* Contraindication to transesophageal echocardiography (TEE)
* Hemodynamic instability before surgery
* Emergency surgery
Early Treatment With Sofosbuvir (SOF) and Ledipasvir (LDV) to Prevent HCV Recurrence After Liver Transplantation (OLT)

The study is a single centre, single arm, open-label, proof of concept study enrolling 20 adult primary liver transplant recipients with genotype 1 HCV infection. Subjects will receive Sofosbuvir (SOF) and Ledipasvir (LDV) starting at time of liver transplantation (OLT) and continues for 12 weeks. Subjects will be receive 24 week post-treatment follow up.

Hepatitis C viral infection (HCV) leading to end-stage liver disease is the leading indication for liver transplant worldwide. HCV recurrence following liver transplantation is universal, associated with 100-fold increase in viremia levels, and runs at an accelerated course, leading to graft cirrhosis in up to 30% of patients within 5 years. Successful eradication of HCV post transplant normalizes the long term survival of HCV positive liver transplant recipients. This study aims to treat HCV infection starting at the time of transplant. The study is a single centre, single arm, open-label,proof of concept study enrolling 20 adult primary liver transplant recipients with genotype 1 HCV infection. Subjects will receive Sofosbuvir (SOF) 400 mg and Ledipasvir (LDV) 90 mg as a fixed dose combination (FDC) tablet starting at time of liver transplantation (OLT) and continues for 12 weeks. Subjects will receive 24 week post-treatment follow up. The study will investigate if the patient has achieved sustained virological response (SVR) 12 weeks after cessation of treatment (SVR12). Furthermore, safety and efficacy of this treatment regimen beginning at the time of transplant will be investigated.

Eligibility Criteria:
Inclusion Criteria:

* Recipient of a first (primary) live or deceased (after brain or cardiac death) donor liver transplant
* Willing and able to provide written informed consent
* Male or Female, age 18-70 years old
* Medical MELD score ≤30 at time of transplant (calculated based on serum bilirubin, creatinine and INR, i.e. not taking exception points into account)
* Quantifiable HCV RNA at time of listing or transplant evaluation
* HCV genotype 1a or 1b infection
* Female patients must have a negative pregnancy test at enrolment

Exclusion Criteria:

* Liver re-transplantation
* Recipients of multiple solid organ transplants
* Estimated GFR \<30ml/min at time of transplant
* Participants transplanted for fulminant hepatic failure
* Participants co-infected with HBV or HIV
* Previous treatment with a Sofosbuvir or Ledipasvir containing regimen
* Participation in an interventional clinical trial within 1 month prior to enrolment
* Known allergies or hypersensitivity to Sofosbuvir or Ledipasvir
* Pregnancy and/or lactation
Qoyangnuptu: Peer Mentor

The goal of this clinical trial is to learn about the impacts of participating in a peer mentor program in a Southwestern Tribal Community. The main questions it aims to answer are:

* In American Indian/Alaska Native communities with unique cultural characteristics, how should a youth-focused sociotechnical behavioral health intervention be designed to encourage sustained engagement and positively impact indicators of behavioral health?;
* How can interactive technical interventions be designed to best support sustained community engagement in a challenged network environment?

Participants will:

* Be trained as peer mentors
* Be trained in how to use the QI App to communicate with mentees
* Guide daily conversation prompts with a group of 3 mentees via the QI App
* Provide daily encouragement to mentees to engage with mindfulness activities on the QI App


Eligibility Criteria:
Inclusion Criteria:

* Member of Southwestern Tribal Community
* Has a smartphone
* Has access to the Internet with the smartphone at least once per day

Exclusion Criteria:

* Has not completed GED/High School Diploma
A Clinical and Histological Analysis of Mesenchymal Stem Cells in Amputation

Patients undergoing semi-elective lower extremity major amputation from complications associated with atherosclerotic limb ischemia will received intra-muscular injections of allogeneic Mesenchymal Stromal Cells in the leg above and below the point of amputation to prevent ischemic wound complications after surgery and decrease the incidence of revision and further amputation. Cohort Groups 1-4 will serve as controls.

This is a phase I single center open label trial study that will enroll twenty-six (26) patients requiring semi-elective lower extremity major amputation within a 30 day period for non-infectious complications related to critical limb ischemia (CLI). After enrollment patients will be scheduled for amputation 7 days after MSC administration. The investigational treatment uses allogeneic bone marrow derived mesenchymal stem cells at the point of care. Allogeneic MSCs will be injected in the gastrocnemius muscle and anterior tibialis muscle of twenty-six (26) patients undergoing major amputation. Through a review of treatment related adverse events over 6 months we will test the hypothesis that allogeneic MSCs do not result in significant cardiovascular, respiratory, or infectious treatment related adverse events. Through an exploratory investigation we will assess the efficacy of MSCs in promoting freedom from gangrene, revision of amputation, and death after major amputation.

Eligibility Criteria:
Inclusion Criteria:

1. Be ≥ 40 and ≤90 years of age.
2. Patients requiring lower extremity major amputation, as determined by an independent vascular specialist.
3. If ulceration or gangrene present, it is distal to malleoli (to allow adequate length of ATM area of approximately 3cm x 10cm x 3 cm)
4. Amputation can safely be performed up to 30 days after screening, as determined by an independent vascular or orthopedic surgeon.
5. Females of childbearing potential must be willing to use one form of birth control for the duration of the study. Female participants must undergo a blood or urine pregnancy test at screening.

Exclusion Criteria:

1. Patients who are pregnant, planning to become pregnant in the next 12 months, or lactating.
2. CHF hospitalization within the last 1 month prior to enrollment.\*
3. Acute coronary syndrome in the last 1 month prior to enrollment.\*
4. HIV positive, or active, untreated HCV as determined by review of medical records.
5. History of cancer within the last 5 years, except basal cell skin carcinoma
6. Inability to provide written informed consent due to cognitive or language barriers (interpreter permitted).
7. Concurrent enrollment in another clinical investigative trial that may alter the outcomes of enrollment in this trial.
8. Any condition requiring immunosuppressant medications (e.g., for treatment of organ transplants, psoriasis, Crohn's disease, alopecia areata).
9. Presence of any clinical condition that in the opinion of the PI or the sponsor makes the patient not suitable to participate in the trial.

   * As defined by the standard definitions of CHF and ACS by the American Heart Association.
Brain PERfusion Evaluation by Contrast-Enhanced UltraSound

The objective of the study is to assess brain tissue perfusion by contrast-enhanced ultrasound perfusion imaging (PerCEUS) in acute brain injuries. More precisely, it aims :

* to evaluate the heterogeneity of brain perfusion and thus diagnose brain tissue hypoperfusion with contrast-enhanced ultrasound.
* to correlate contrast-enhanced ultrasound with perfusion measurements by usual multimodal monitoring.

The main aim is to evaluate the heterogeneity of brain perfusion, thus diagnosing brain tissue hypoperfusion with PerCEUS, then to correlate it with the usual multimodal monitoring.

Earlier after hospitalization in neurointensive care, when the study physician needs to realize a contrast ultrasound imaging and without delaying any emergency procedure, a PerCEUS will be performed in patients with an acute brain injury. After acquisition, data from PerCEUS will be transferred to an external evaluation unit and analysed offline, using commercially available software Qlab (Philips ®). According to the localization of acute brain injuries with magnetic resonance imaging (MRI) and/or computed tomography (CT), several regions-of-interest (ROI, at least three in each area) will be chosen :

* Area 1 : in the core of the lesion (supposed non perfused)
* Area 2 : just next to the lesion (supposed hypoperfused)
* Area 3 : in the saner hemisphere, symmetrically to area 2 each time it's possible (supposed well-perfused).

Every parameters of multimodal monitoring used at the moment of PerCEUS will be relieved :

* intracranial pressure (ICP), cerebral perfusion pressure (CPP), mean arterial pressure (MAP)
* mean flow velocity (MFV) by transcranial doppler (TCD)
* regional cerebral oxygen saturation (rSO2) by Near infrared spectroscopy (NIRS)
* jugular venous oximetry (SjvO2).

The actual PerCEUS measurement takes place at the bedside, is performed by the study physician, and takes about 5 minutes.

The trial duration per patient is 30 minutes, ending after 25 minutes of oversight

Eligibility Criteria:
Inclusion Criteria:

* Age ≥18
* Intensive care unit admission for acute brain injury
* Proven acute brain injury by CT and/or MRI
* Requiring a contrast ultrasound imaging
* Informed consent of patient or relative

Exclusion Criteria:

* Pregnancy
* Not sufficient temporal window
* Contraindications to Sonovue ® : acute coronary syndromes, severe ischemic heart disease (requiring revascularization), pulmonary arterial hypertension \> 90 mmHg, right-left shunt, ARDS, dobutamine's use, known allergy or adverse reaction to Sonovue®
* Patient on State Medical Assistance
The Role of Short-course Ceftriaxone Therapy in the Treatment of Severe Nontyphoidal Salmonella Enterocolitis

The purpose of the investigators study is to evaluate if short-course of ceftriaxone therapy could shorten the clinical courses of severe nontyphoidal Salmonella enterocolitis in children and the excretion of Salmonella in feces.

Nontyphoidal salmonellae (NTS) is one of the most important pathogens of gastroenteritis in humans. Although most nontyphoidal Salmonella infections result in self-limited gastroenteritis, invasive infections such as bacteremia, meningitis or extraintestinal infection could also occur. Antimicrobial therapy is not recommended for routine treatment of nontyphoidal salmonellosis and effective antibiotic treatment is essential if NTS infection spreads beyond the intestine such as bacteremia, meningitis or osteomyelitis.

Although some reports revealed that antimicrobial therapy may be beneficial for shortening the clinical courses of severe NTS enterocolitis, most of them were based on clinical observations, not based on the results of objective examinations. Thus, the use of antibiotics in the treatment of patients with severe NTS gastroenteritis is still controversial in clinical practice.

As a third generation cephalosporin, ceftriaxone has a higher concentration than conventional antibiotics such as ampicillin and trimethoprim-sulfamethoxazole in the intestinal mucosa and gallbladder. Besides, ceftriaxone maintains relatively lower resistance rate in Salmonella than those of other conventional antibiotics. So the purpose of our study is to evaluate if short-course of ceftriaxone therapy could shorten the clinical courses of severe NTS enterocolitis in children and the excretion of Salmonella in feces. The investigators think that the study may be helpful for clinicians in the treatment of severe NTS enterocolitis in children, especially on the judgments of the choices and the treatment cures of antibiotics.

Eligibility Criteria:
Inclusion Criteria:

* Children with suspected severe Salmonella enterocolitis
* defined as those with a high fever (core body temperature ≥ 38.5℃) persisting for longer than 48 hours
* diarrhea with mucous and bloody-tinged stool.

Exclusion Criteria:

* Children with a toxic appearance, severe vomiting and abdominal distension
* suggestive of sepsis or toxic megacolon, those with an increased risk of invasive NTS diseases
* immunosuppressive illnesses
* had taken antibiotics during the 7 days before the visit will be excluded.
Stimulation of Parents' Self-efficacy Beliefs and Emotion Coaching Practices (H2M1)

This research compared the efficacy of two parenting interventions that vary according to the number and the nature of variables in reducing preschoolers' externalizing behavior (EB). The goal was to identify which parenting intervention format (one-variable versus two-variable) caused higher behavioral adjustment in children.

The first format was a one-variable intervention manipulating parental self-efficacy beliefs. The second format was a two-variable intervention manipulating both parents' self-efficacy beliefs and emotion coaching practices. The two interventions shared exactly the same design, consisting of eight parent group sessions. Effect on children's EB and observed behaviors were evaluated through a multi-method assessment at three points (pre-test, post-test and follow-up).

Eligibility Criteria:
Inclusion Criteria:

* children in the clinical or borderline range of the EB scale (cut-off = 21 or higher) of the Child Behavior Checklist preschool form (Achenbach \& Rescorla, 2000a)
* three to six years old and still in kindergarten at the beginning of the intervention

Exclusion Criteria:

* children with intellectual disabilities (average IQ \< 5.5)
* highly gifted children (average IQ \>14.5)
Impact of Chromium Supplementation on Glucido-lipidic Metabolism, Oxidative Stress and Inflammatory State in Patients with Gestational Diabetes

Our study aims to explore the influence of dietary chromium supplementation in the form of chromium picolinate, at different doses (200 µg and 400 µg per day), on the health of pregnant women with gestational diabetes. This study will also provide more information on the safety of this type of supplementation during pregnancies complicated by gestational diabetes mellitus.

The main questions it aims to answer are:

* Does chromium supplementation at various doses in women with gestational diabetes mellitus truly influence their glucido-lipidic metabolism, oxidative/antioxidant balance, and inflammatory state? If so, is it beneficial or detrimental?
* If this supplementation is beneficial, which dose is the most appropriate?
* Do these types of supplementation have any side effects on the health of the mother and fetus? The participants will take chromium supplements for 6 weeks (supplemented groups) while the control participants will not take them (healthy and diabetic control groups).

Chromium-supplemented participants will undergo a medical check-up every 02 weeks to closely monitor their health status and detect any potential side effects at an early stage.

Researchers will compare the biochemical profile, oxidative stress status, and inflammation markers between chromium-supplemented and non-supplemented participants to assess the impact of this trace element.

Researchers will compare the effects of chromium supplements at different doses with each other.


Eligibility Criteria:
Inclusion Criteria:

* Healthy pregnant women:

  * Whose their gestational age is 28 weeks
  * They have no pathology or complication associated with their pregnancy.
* Pregnant women with gestational diabetes mellitus:

  * They will be selected according to the criteria of the one-step method for screening for gestational diabetes mellitus established by the WHO.
  * They have no other pathology or complication associated with pregnancy.
  * They are subjected to insulin therapy and a low-calorie diet, rich in protein, fiber and beneficial lipids (they will all asked to keep their medical treatment prescribed by their doctor).
* All women involved in this study will be systematically supplemented with 60 mg/d iron and 400 mg/d vitamin B9 during pregnancy as recommended by WHO.

Exclusion Criteria:

* Pregnant women with unrecognized diabetes, type I or type II, will not be involved in this study.
* Pregnant women who were supplemented before one month or during pregnancy, or who will need other micronutrient supplements during the study to avoid their influence on the results.
* Pregnant women who develop other health complications will be removed from the study and replaced by others.
* Women with gestational diabetes mellitus who were unable to complete chromium supplementation up to 6 weeks will be excluded from the study and replaced by others.
Investigation of the Effectiveness of Myofascial Release Technique in Young Basketball Players

In this study, it is aimed to remove the limitations that cause asymmetry and weak connections in functional movement patterns with myofascial relaxation method to be applied to certain muscles and to remove the obstacles in front of the power factor as a result of its application, to reach the highest efficiency of the athlete's performance and to reduce the risk of injury in the musculoskeletal system.Study; It was planned as a control group (n:30) and an intervention group (n:30). Apart from routine training, the intervention group will be treated twice a week for 6 weeks before the training. On the other hand, no application will be made to the control group other than routine training. The evaluations are; It will be done at the beginning of the study and after the 6-week period.

The study will be randomly divided into two groups and it is planned to include 30 people in each group.

After evaluations (demographic information, functional movement screening test (FMS), t agility test, vertical jump test, muscle strength test, muscle viscoelasticity and star balance test) were made at the beginning of the study in the intervention group (n=30), twice a week for 6 weeks. Myofascial release technique will be performed before the training. Final evaluations will be made 6 weeks after starting the intervention.

The control group (n=30) was excluded from the routine training period for 6 weeks after evaluations (demographic information, functional movement screening test (FMS), T agility test, vertical jump test, muscle strength test, muscle viscoelasticity and star balance test) were made at the beginning of the study. No action will be taken. At the end of 6 weeks, evaluations will be made again.

Eligibility Criteria:
Inclusion Criteria:

* To be playing basketball for at least 6 months
* Being between the ages of 10-16
* Being a man

Exclusion Criteria:

* Having had any surgical operation in the last 6 months.
* Having had a lower/upper extremity injury in the last 3 months.
* A history of anterior cruciate ligament repair
* History of meniscus repair
* History of Achilles tendon repair
* Evaluation intervals to coincide with the pre-season period
Prospective Epidemiological Study Of The Prevalence Of HLA-B*5701

This is a study to determine the prevalence of a genetic marker, HLA-B5701, in the UK population. HLA-B\*5701 has been strongly associated with the risk of an allergic reaction to a HIV medicine, Abacavir. The allergic reaction is known as a hypersensitivity reaction.

The study is a prospective study inviting HIV-1 positive patients over the age of 18 years to participate. Each participant will complete one study visit. They will be asked for details of their background including their age, sex, ethnicity, country of origin and parental country of origin.

They will be asked to give two samples to test for the presence of the genetic marker HLA-B\*5701. The two samples are:

* A cheek swab
* A blood sample

In selected centres patients may be asked to provide up to two additional blood samples. These samples will be used to help develop and validate new methods of determining HLA-B\*5701 testing.


Eligibility Criteria:
Inclusion criteria:

* HIV-1 infected patients over 18 years of age
* Patient willing \& able to understand and provide written informed consent

Exclusion criteria:

* None